<html>
<head>
<title>ACP </title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<META NAME="Ref1">
</head>

<body bgcolor="B6b6b6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="214d7b" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><a name="Top"></a><img src="../Assets/ISHCCBtitle.gif" width="650" height="50"></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ISHandCCB.html"><img src="../Assets/ACP1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ISHandCCB.html"><img src="../Assets/ACP2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ISHandCCB.html"><img src="../Assets/ACP3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ISHandCCB.html"><img src="../Assets/ACP4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ISHandCCB.html"><img src="../Assets/ACP5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ISHandCCB.html"><img src="../Assets/ACP6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/ACPheader.gif" width="330" height="50" align="baseline"><img src="../Assets/ACPheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="90%" border="0">
                <tr> 
                  <td colspan="2"> <p class="BEsection"><font color="#3399CC">Therapeutics</font></p>
                    <table width="100%" border="0">
                      <tr> 
                        <td bgcolor="#6699cc"><font size="4"><strong><a name="diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients"></a>Review: 
                          Isolated systolic hypertension increases mortality and 
                          morbidity in elderly persons and should be treated</strong></font></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 2000 Sept-Oct;133:41.<BR>
                    </p>
                    <P CLASS="Citation">Staessen JA, Gasowski J, Wang JG, et al. 
                      <b>Risks of untreated and treated isolated systolic hypertension 
                      in the elderly: meta-analysis of outcome trials.</b> Lancet. 
                      2000 Mar 11;355:865-72. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="AbsHd"><font color="#3399CC">Questions</font></p>
                    <P CLASS="AbsTxt">In elderly persons, what are the risks associated 
                      with isolated systolic hypertension (<img src="../Assets/greaterthansign.gif" width="6" height="9"> 
                      160 mm Hg with diastolic blood pressure [BP] &lt; 95 mm 
                      Hg), and what is the magnitude of the benefit associated 
                      with treatment? </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Data sources</font></p>
                    <P CLASS="AbsTxt">Studies were identified from 10 published 
                      overviews and 2 reports from trialist collaborations.</p>
                    <P CLASS="AbsHd"><font color="#3399CC">Study selection</font></p>
                    <P CLASS="AbsTxt">Controlled trials were selected if elderly 
                      persons with isolated systolic hypertension were enrolled. 
                      Trials were excluded if all the study participants had comorbid 
                      conditions, such as stroke; if specialized care was compared 
                      with routine antihypertensive agents; and if the study was 
                      a preliminary evaluation for a larger study. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Data extraction</font></p>
                    <P CLASS="AbsTxt">Data were extracted on study quality, patient 
                      characteristics, antihypertensive treatment, duration and 
                      length of follow-up, and outcomes (all-cause and cardiovascular 
                      mortality, cardiovascular complications, all strokes, and 
                      all coronary events). Strokes did not include transient 
                      ischemic attacks. Cardiovascular complications included 
                      coronary artery disease (myocardial infarction and sudden 
                      death), stroke, and vascular disorders. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Main results</font></p>
                    <P CLASS="AbsTxt">8 trials (15 693 patients) were included. 
                      Mean age range was 62 to 76 years, median follow-up was 
                      3.8 years, prevalence of smoking at baseline was 16%, and 
                      31% of participants had <img src="../Assets/greaterthansign.gif" width="6" height="9">1 
                      cardiovascular complication at baseline. All-cause mortality 
                      was positively associated with systolic BP (P &lt; 0.001) 
                      and negatively associated with diastolic BP (P = 0.05): 
                      With any given increase in systolic BP, a lower diastolic 
                      BP increased the risk for death. For each 10-mm increase 
                      in systolic BP, an increase was shown in all-cause mortality 
                      (hazard ratio [HR] 1.26, 95% CI 1.13 to 1.40), cardiovascular 
                      death (HR 1.22, CI 1.06 to 1.40), cardiovascular events 
                      (HR 1.15, CI 1.04 to 1.28), and stroke (HR 1.22, CI 1.04 
                      to 1.40) but not coronary events (HR 1.07, CI 0.91 to 1.26). 
                      For each 5-mm Hg increase in diastolic BP, a decrease in 
                      all-cause mortality was found (HR 0.95, CI 0.89 to 1.00). 
                    </p>
                    <P CLASS="AbsTxt">With treatment, the mean reduction was 10.4 
                      (range 6.9 to 18.2) in systolic BP and 4.1 (range 2.3 to 
                      8.3) mm Hg in diastolic BP. An improvement in all outcomes 
                      was found when results for all trials were pooled (Table). 
                      Summary analysis showed that all outcomes improved with 
                      treatment even across subgroups based on sex, age, systolic 
                      BP, pulse pressure, previous cardiovascular complications, 
                      and smoking status. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Main outcome measures</font></p>
                    <P CLASS="AbsTxt">Combined nonfatal and fatal stroke, nonfatal 
                      myocardial infarction (MI) or cardiac death, major coronary 
                      heart disease (CHD), and major CVD.</p>
                    <P CLASS="AbsHd"><font color="#3399CC">Conclusion</font></p>
                    <P CLASS="AbsTxt">Isolated systolic hypertension and wide 
                      pulse pressure in elderly persons increase the risk for 
                      mortality and morbidity. Treatment reduces this risk. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Source of funding: 
                      Not stated.</p>
                    <P CLASS="Reprint">For correspondence: Dr. J.A. Staessen, 
                      Studie-co&ouml;rdinatiecentrum, Laboratorium Hypertensie, 
                      Campus Gasthuisberg, Gebouw Onderwijs en Navorsing, Herestraat 
                      49, B-3000 Leuven, Belgium. FAX 32-16-347106. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="TablTitl">Treatment of 
                      isolated systolic hypertension in elderly persons*</p>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody>
                        <tr valign=top> 
                          <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
                            at mean 3.8 y </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Odds 
                            ratio reduction (95% CI) </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">NNT 
                            (CI) </font></th>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All-cause 
                            mortality </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">13% 
                            (2 to 22) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">59 
                            (55 to 64) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
                            mortality </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">18% 
                            (4 to 29) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">79 
                            (72 to 89) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            cardiovascular events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26% 
                            (17 to 34) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26 
                            (25 to 27) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            stroke events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">30% 
                            (18 to 41) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">48 
                            (45 to 51) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            coronary events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">23% 
                            (10 to 34) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">64 
                            (59 to 70) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                      </tbody>
                    </table>
                    <P CLASS="TablFootn"><font class=textblack 
      face="arial, helvetica, sans-serif" size=2><font 
      class=pageboldgrn size=2>*Abbreviations defined in <a 
      href="../Assets/Glossary2.html" target="_blank">Glossary</a>. 1 trial was 
                      not a randomized controlled trial; reanalysis without this 
                      trial did not alter outcomes significantly.</font></font></p>
                    <hr size=2 color=#3399CC> <P CLASS="CmHd"><font color="#3399CC">Commentary</font></p>
                    <P CLASS="CmTxt">Clinicians, be comforted! This sophisticated 
                      meta-analysis by Staessen and colleagues confirms what we 
                      already know: Systolic BP better predicts cardiovascular 
                      events than does diastolic BP, and absolute 5-year benefits 
                      of antihypertensive drug therapy are greater among persons 
                      with higher baseline risks, such as men, older adults, and 
                      persons with known cardiovascular disease. It also confirms 
                      several observational studies that show that wider pulse 
                      pressure—a measure dependent on ventricular ejection, timing 
                      of blood pressure waves, and arterial stiffness—is associated 
                      with higher baseline risks. </p>
                    <P CLASS="CmTxt">Should we now routinely use pulse pressure 
                      rather than systolic and diastolic BP measurements alone? 
                      Not yet. First, for those who rely on risk assessment to 
                      determine when benefits of treatment are likely to outweigh 
                      harms, we need changes in current risk-assessment tools 
                      to incorporate pulse pressure. Second, antihypertensive 
                      agents have multiple and heterogeneous effects, and the 
                      pathophysiology of hypertension is complex; all agents are 
                      not equivalent despite equivalent BP reduction (1). We do 
                      not yet know whether differences in drug benefits are caused 
                      by differences in reducing pulse pressure. </p>
                    <P CLASS="CmTxt">Active research to improve evidence-based 
                      care of patients with hypertension is alive and well. The 
                      results of these studies are still subject to change. What 
                      will the bottom line be? Clinicians, stand by! </p>
                    <P CLASS="CmAuth1">Ronald T. Ackermann, MD<br>
                      Cynthia D. Mulrow, MD <BR>
                      Audie L. Murphy Memorial Veterans Hospital<BR>
                      San Antonio, Texas, USA</p>
                    <HR SIZE=2 COLOR=#3399CC> <br> <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong>Reference</strong></td>
                      </tr>
                    </table>
                    <P CLASS="CmRef">1. <b>ALLHAT Collaborative Research Group</b>. 
                      Major cardiovascular events in hypertensive patients randomized 
                      to doxazosin vs chlorthalidone: the Antihypertensive and 
                      Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 
                      JAMA. 2000;283:1967-75.</p>
                    <P CLASS="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><font 
      class=copyrightblue face="arial, sans-serif" color=#3399cc 
      size=1>Copyright &copy;2001 American College of Physicians – American Society 
                      of Internal Medicine</font> </font></font></p>
                    <p class="CmRef" align="right">&nbsp;</p></td>
                </tr>
                <tr> 
                  <td width="87%"><div align="center"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong></div></td>
                  <td width="13%"><div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div></td>
                </tr>
              </table>
              <p class="BEsection" align="right">&nbsp;</p>
              </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="528ece"> 
            <div align="center"></div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
